Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Michael H TomassonShinsuke IidaRuben NiesvizkyMohamad MohtyNizar J BahlisJoaquin Martinez-LopezGuenther KoehnePaula Rodriguez OteroH Miles PrinceAndrea ViqueiraEric LeipUmberto ConteSharon T SullivanAlexander M LesokhinPublished in: HemaSphere (2024)